Novel molecular insights and public omics data in pulmonary hypertension

Pulmonary hypertension is a rare disease with high morbidity and mortality which mainly affects women of reproductive age. Despite recent advances in understanding the pathogenesis of pulmonary hypertension, the high heterogeneity in the presentation of the disease among different patients makes it difficult to make an accurate diagnosis and to apply this knowledge to effective treatments. Therefore, new studies are required to focus on translational and personalized medicine to overcome the lack of specificity and efficacy of current management. Here, we review the majority of public databases storing `omics' data of pulmonary hypertension studies, from animal models to human patients. Moreover, we review some of the new molecular mechanisms involved in the pathogenesis of pulmonary hypertension, including non-coding RNAs and the application of `omics' data to understand this pathology, hoping that these new approaches will provide insights to guide the way to personalized diagnosis and treatment.

Automated summary

Pulmonary hypertension is a rare but high morbidity and mortality disease mainly affecting women of reproductive age. Despite recent advances in understanding the pathogenesis, the high heterogeneity in presentation among different patients makes accurate diagnosis and effective treatment challenging. Therefore, new studies focusing on personalized medicine are needed to overcome the lack of specificity and efficacy in current management.